Site initiation visits have become a paradox: the longer they get, the less useful they are. Advarra’s Christine Senn points to a concrete symptom: across 16 SIV training decks her team reviewed, slide counts ranged from 75 pages to 381 pages. A 381-page deck is not a training tool; it is a compliance artifact, and sites navigating it are unlikely to absorb the handful of protocol-specific details that actually determine whether a trial runs cleanly.
The proposed fix, detailed in Part 3 of Advarra’s SIV series, is structural rather than cosmetic: split what currently arrives as one sprawling event into three distinct layers. The first holds reusable, role-based content covering GCP principles, informed consent, source documentation, and safety reporting basics, material that a qualified site coordinator has seen in some form on every prior trial and does not need rebuilt from scratch each time. The second layer covers vendor and platform mechanics, EDC navigation, IRT/RTSM workflows, central lab portals, delivered asynchronously and just in time rather than during a live session the site will still have to repeat through vendor-required certification anyway. The third layer is the live SIV itself, reserved for protocol-specific risk: eligibility nuances, dose modification rules, disease-specific assessments, and the operational exceptions that genuinely differ from every other study the site has run.
The role-based dimension matters as much as the layer structure. A pharmacist, a data manager, and an imaging contact do not share the same training needs, yet the current single-deck model treats them as interchangeable. Disaggregating content by role reduces the hours any one staff member spends in irrelevant review, which is not a trivial concern: Johns Hopkins Medicine’s published standard cost schedule flags up to 10 hours of radiology staff time just for protocol review, training, and initiation visit participation in imaging-enabled studies. Multiply that across every vendor system, every role, and every concurrent trial a site is running, and the overhead compounds quickly.
The model’s real ceiling is standardization across the industry rather than within a single sponsor’s program. Senn’s argument, which will inform a white paper the Advarra-facilitated Site-Sponsor Consortium plans to release in fall 2026, is that every sponsor building its own reusable generic module still leaves sites absorbing the same fundamentals in slightly different wrappers across dozens of studies. The white paper’s reception among the consortium’s member organizations will show whether that collective appetite for shared standards exists, or whether competitive instincts keep each sponsor’s generic layer proprietary.
Source link: https://www.advarra.com/blog/a-better-siv-model-starts-by-separating-the-common-from-the-unique/
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
